TCIM
HRTX icon

TIAA CREF Investment Management’s Heron Therapeutics HRTX Stock Holding History

TIAA CREF Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$2.81M Sell
114,804
-6,723
-6% -$176K ﹤0.01% 1808
2018
Q4 		$3.15M Sell
121,527
-2,799
-2% -$77K ﹤0.01% 1667
2018
Q3 		$3.94M Sell
124,326
-5,044
-4% -$188K ﹤0.01% 1736
2018
Q2 		$5.03M Buy
129,370
+5,071
+4% +$161K ﹤0.01% 1591
2018
Q1 		$3.43M Buy
124,299
+11,765
+10% +$267K ﹤0.01% 1799
2017
Q4 		$2.04M Sell
112,534
-10,291
-8% -$168K ﹤0.01% 2118
2017
Q3 		$1.98M Buy
122,825
+1,025
+0.8% +$16.1K ﹤0.01% 2172
2017
Q2 		$1.69M Buy
121,800
+18,105
+17% +$262K ﹤0.01% 2279
2017
Q1 		$1.55M Buy
103,695
+12,392
+14% +$172K ﹤0.01% 2284
2016
Q4 		$1.2M Sell
91,303
-4,469
-5% -$70.1K ﹤0.01% 2438
2016
Q3 		$1.65K Sell
95,772
-453
-0.5% -$8.4K ﹤0.01% 2275
2016
Q2 		$1.74M Buy
96,225
+7,235
+8% +$141K ﹤0.01% 2212
2016
Q1 		$1.69M Sell
88,990
-11,165
-11% -$220K ﹤0.01% 2175
2015
Q4 		$2.67M Sell
100,155
-12,559
-11% -$336K ﹤0.01% 1987
2015
Q3 		$2.75M Buy
112,714
+12,595
+13% +$420K ﹤0.01% 1951
2015
Q2 		$3.12M Buy
100,119
+23,738
+31% +$447K ﹤0.01% 2013
2015
Q1 		$1.11M Hold
76,381
– – ﹤0.01% 2563
2014
Q4 		$768K Buy
76,381
+3,211
+4% +$26.2K ﹤0.01% 2804
2014
Q3 		$610K Buy
73,170
+679
+0.9% +$6.32K ﹤0.01% 2888
2014
Q2 		$893K Buy
+72,491
New +$866K ﹤0.01% 2780

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TIAA CREF Investment Management's HRTX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Heron Therapeutics (HRTX) stake by 5.5% in Q1 2019, selling an estimated $176K and leaving 114,804 shares worth $2.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

TIAA CREF Investment Management first reported a position in HRTX in Q2 2014 and has held it in 20 quarters since. The position peaked at $5.03M in Q2 2018. 198 funds tracked by Wall St. Rank hold HRTX as of Q1 2019.

  • TIAA CREF Investment Management held 114,804 shares of Heron Therapeutics worth $2.81M as of Q1 2019.
  • TIAA CREF Investment Management sold 6,723 Heron Therapeutics shares in Q1 2019, an estimated $176K.
  • Heron Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1808 holding.
  • TIAA CREF Investment Management first reported a position in Heron Therapeutics in Q2 2014 and has held it in 20 quarters since.
  • TIAA CREF Investment Management's Heron Therapeutics position peaked at $5.03M in Q2 2018.
  • 198 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.